Maxion Therapeutics

Maxion Therapeutics is a private biotechnology company based in Cambridge, United Kingdom, founded in 2020.

It specializes in drug discovery, clinical trials, and precision medicine, focusing on developing innovative therapeutics for chronic pain, autoimmune disorders, and cardiovascular diseases. The company is led by a team of experienced professionals with strong backgrounds in the pharmaceutical industry. The cornerstone of Maxion's innovation is its proprietary KnotBody® technology, which combines naturally occurring mini-proteins called knottins with antibodies. This hybrid approach allows for the development of therapeutics that effectively target ion channels and G-protein-coupled receptors, addressing conditions that are difficult to treat with traditional methods. Maxion is currently in the late-stage R&D phase, having raised approximately $90.5 million, including a significant Series A round of $72 million. The company is expanding its research and development capabilities to accelerate its drug development pipeline.